Trial 4B-13-3


An Integrated Phase II/III, Open Label, Randomized, Parallel and Controlled Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen In Patients with Non-Muscle Invasive Bladder Carcinoma in Situ Disease (“NMIBCis”, meaning CIS and CIS with TAand/or T1) and who have failed BCG Therapy and Refused Cystectomy

Type: Treatment
Phase: Phase II/III
Status: Not Open (Never Opened)
Treatments:
Randomized: Not Asked
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Siamak Daneshmand, M.D.
Other Trial Staff:  

Staff may log in to see study documents.







For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.